{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:07:24Z","timestamp":1792595244204,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004435","name":"Universidad de Navarra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004435","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Amnestic mild cognitive impairment (aMCI) is considered a precursor to Alzheimer\u2019s disease (AD). Since cerebral amyloid aggregation and neurodegeneration can be detected at an early stage, it can serve as a diagnostic aid. This study aimed to determine the predictive value of Amyloid-PET and FDG-PET in determining progression to AD among patients with aMCI.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This study recruited 145 patients with aMCI from October 2013 to March 2021. The patients were classified into four groups based on whether Amyloid-PET (A) and FDG-PET (N) were positive (+) or negative (-). The patients were then clinically followed to establish progression to dementia due to AD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Amyloid-PET demonstrated high sensitivity (100% in year 1, 94.67% in year 4) and a high negative predictive value (100% in year 1, 88.24% in year 4). FDG-PET exhibited a high negative predictive value initially (94.59% in year 1), and during follow-up, both specificity (85%) and positive predictive value (88%) increased. The conversion from aMCI to AD had a global mean time of 39.95 months. However, progression to AD was slower in amyloid-negative patients versus amyloid-positive patients (75.07 [CI 56.54\u201381] vs. 32.59 months [CI 20.56\u201340.74] months). Taking both tests together, the time to conversion was faster in A+\/N\u2009+\u2009versus A+\/N- patients (27.79 [CI 20.40\u201333.21] vs. 37.38 [CI 20.73\u201348.26] months).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Among patients with aMCI, those with a positive Amyloid-PET and an AD pattern on FDG-PET progressed to dementia significantly earlier versus those with a positive Amyloid-PET only. Using both biomarkers during the initial diagnosis enhances the prediction of short-term conversion.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number<\/jats:title>\n            <jats:p>Not applicable. It is not a clinical trial.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00259-025-07275-2","type":"journal-article","created":{"date-parts":[[2025,4,20]],"date-time":"2025-04-20T23:52:49Z","timestamp":1745193169000},"page":"3567-3577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer\u00b4s disease in the clinical practice"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1469-0826","authenticated-orcid":false,"given":"Beatriz","family":"Echeveste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar Fernando","family":"Guill\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genoveva","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Villino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Riverol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Arbizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"7275_CR1","unstructured":"Vos T et al. Prevalence and prognosis of Alzheimer\u2019s disease at the mild cognitive impairment stage. Brain. 2015;1\u201312."},{"issue":"19","key":"7275_CR2","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2015.4668","volume":"313","author":"WJ Jansen","year":"2018","unstructured":"Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FRJ, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2018;313(19):1924\u201338.","journal-title":"JAMA"},{"issue":"4","key":"7275_CR3","first-page":"742","volume":"83","author":"AG Vlassenko","year":"2018","unstructured":"Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, et al. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Ann Neurol. 2018;83(4):742\u201353.","journal-title":"Ann Neurol"},{"key":"7275_CR4","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1007\/s00259-013-2458-z","volume":"40","author":"J Arbizu","year":"2013","unstructured":"Arbizu J, Prieto E, Mart\u00ednez-Lage P, et al. Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer\u2019s disease dementia. Eur J Nucl Med Mol Imaging. 2013;40:1394\u2013405. https:\/\/doi.org\/10.1007\/s00259-013-2458-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"7275_CR5","first-page":"1045","volume":"84","author":"A Prestia","year":"2015","unstructured":"Prestia A, Caroli A, Van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, et al. Prediction of dementia in patients with MCI based on core diagnostic markers for alzheimer. Neurology. 2015;84(11):1045\u201353.","journal-title":"Neurology"},{"issue":"11","key":"7275_CR6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","volume":"19","author":"G Ch\u00e9telat","year":"2020","unstructured":"Ch\u00e9telat G, Villemagne VL, Villain N, et al. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias. Lancet Neurol. 2020;19(11):951\u201362. https:\/\/doi.org\/10.1016\/S1474-4422(20)30314-8.","journal-title":"Lancet Neurol"},{"key":"7275_CR7","doi-asserted-by":"publisher","unstructured":"Frisoni GB, Festari C, Massa F, Cotta Ramusino M, Orini S, Aarsland D, Agosta F, Babiloni C, Borroni B, Cappa SF, Frederiksen KS, Froelich L, Garibotto V, Haliassos A, Jessen F, Kamondi A, Kessels RP, Morbelli SD, O\u2019Brien JT, Otto M, Perret-Liaudet A, Pizzini FB, Vandenbulcke M, Vanninen R, Verhey F, Vernooij MW, Yousry T, Boada Rovira M, Dubois B, Georges J, Hansson O, Ritchie CW, Scheltens P, van der Flier WM, Nobili F. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. Lancet Neurol. 2024;23(3):302\u2013312. https:\/\/doi.org\/10.1016\/S1474-4422(23)00447-7. PMID: 38365381.","DOI":"10.1016\/S1474-4422(23)00447-7"},{"key":"7275_CR8","doi-asserted-by":"publisher","unstructured":"J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R. Y. K.,\u2026 Demattos, R. B.(2021). A randomised, double-blind, placebo-controlled, phase 2 study of lecanemab in early Alzheimer\u2019s disease.Alzheimer\u2019s Research & Therapy, 13(1), 80. https:\/\/doi.org\/10.1186\/s13195-021-00817-2.","DOI":"10.1186\/s13195-021-00817-2"},{"issue":"1","key":"7275_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2022","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Sims JR. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2022;388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"issue":"18","key":"7275_CR10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels SR, Ardayfio PA, Andersen SW, Sims JR. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2100708.","journal-title":"N Engl J Med"},{"issue":"1","key":"7275_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.14283\/jpad.2020.74","volume":"8","author":"SL Lowe","year":"2021","unstructured":"Lowe SL, Willis BA, Hawdon A, Natanegara F, Chua L, Foster J, Bateman RJ. Donanemab (LY3002813) phase 1b study in Alzheimer\u2019s disease: rapid and sustained reduction of brain amyloid measured by Florbetapir F18 imaging. J Prev Alzheimer\u2019s Disease. 2021;8(1):14\u201320. https:\/\/doi.org\/10.14283\/jpad.2020.74.","journal-title":"J Prev Alzheimer\u2019s Disease"},{"key":"7275_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Ageing-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:270\u20139.","journal-title":"Alzheimer\u2019s Dement"},{"key":"7275_CR13","doi-asserted-by":"publisher","unstructured":"Burns A, Brayne C, Folstein M. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. M., Folstein S, Folstein, McHugh P. Journal of Psychiatric Research (1975) 12, 189\u2013198. Int J Geriatr Psychiatry. 1998. https:\/\/doi.org\/10.1002\/(SICI)1099-1166(199805)13-5-285-AID-GPS753-3.0.CO-2-V","DOI":"10.1002\/(SICI)1099-1166(199805)13-5-285-AID-GPS753-3.0.CO-2-V"},{"key":"7275_CR14","doi-asserted-by":"publisher","DOI":"10.1017\/S1041610298005377","author":"P B\u00f6hm","year":"1998","unstructured":"B\u00f6hm P, Pe\u00f1a-Casanova J, Aguilar M, Hern\u00e1ndez G, Sol JM, Blesa R. Clinical validity and utility of the interview for deterioration of daily living in dementia in Spanish-speaking communities. Int Psychogeriatr. 1998. https:\/\/doi.org\/10.1017\/S1041610298005377.","journal-title":"Int Psychogeriatr"},{"key":"7275_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(82)90033-4","author":"JA Yesavage","year":"1982","unstructured":"Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res. 1982. https:\/\/doi.org\/10.1016\/0022-3956(82)90033-4.","journal-title":"J Psychiatr Res"},{"key":"7275_CR16","doi-asserted-by":"crossref","unstructured":"Ivnik RJ, Smith GE, Lucas JA, Tangalos EG, Kokmen E. Free and cued selective reminding test: MOANS norms. J Clin Exp Neuropsychol. 1997.","DOI":"10.1080\/01688639708403753"},{"key":"7275_CR17","volume-title":"Guide to using the coloured progressive matrices","author":"J Raven","year":"1958","unstructured":"Raven J. Guide to using the coloured progressive matrices. Oxford: H.K. Lewis; 1958."},{"key":"7275_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1037\/h0054651","volume":"18","author":"JR Stroop","year":"1935","unstructured":"Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18:643\u201362.","journal-title":"J Exp Psychol"},{"key":"7275_CR19","unstructured":"Wechsler D. WAIS-III administration and scoring manual. 1997."},{"key":"7275_CR20","doi-asserted-by":"publisher","DOI":"10.2466\/pms.1958.8.3.271","author":"RM Reitan","year":"1958","unstructured":"Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958. https:\/\/doi.org\/10.2466\/pms.1958.8.3.271.","journal-title":"Percept Mot Skills"},{"key":"7275_CR21","volume-title":"The Boston naming test","author":"EF Kaplan","year":"2001","unstructured":"Kaplan EF, Goodglass H, Weintraub S. The Boston naming test. Volume 2. Philadelphia: Lea Febiger; 2001."},{"key":"7275_CR22","doi-asserted-by":"publisher","unstructured":"Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, Mathis CA, McConathy J, Nordberg A, Sabri O, Seibyl JP, Stokes MK, Van Laere K. SNMMI Procedure Standard\/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. J Nucl Med. 2016;57(8):1316-22. https:\/\/doi.org\/10.2967\/jnumed.116.174615. PMID: 27481605.","DOI":"10.2967\/jnumed.116.174615"},{"key":"7275_CR23","unstructured":"Life Molecular Imaging. Neuraceq (florbetaben 18F) solution for injection. Summary of Product Characteristics. European Medicines Agency. Published February 20, 2014. Accessed February 25, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/neuraceq-epar-product-information_en.pdf"},{"key":"7275_CR24","unstructured":"Eli Lilly and Company. Amyvid (florbetapir 18F) solution for injection. Summary of Product Characteristics. European Medicines Agency. Published on January 14, 2013. Accessed February 25, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/amyvid-epar-product-information_en.pdf"},{"key":"7275_CR25","unstructured":"GE Healthcare. Vizamyl (flutemetamol 18F) solution for injection. Summary of Product Characteristics. European Medicines Agency. Published on January 22, 2021. Accessed February 25, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vizamyl-epar-product-information_en.pdf"},{"key":"7275_CR26","doi-asserted-by":"publisher","unstructured":"Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, N\u00e5gren K, Darcourt J, Kapucu OL, Tatsch K, Bartenstein P, Van Laere K, European Association of Nuclear Medicine Neuroimaging Committee. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36(12):2103-10. https:\/\/doi.org\/10.1007\/s00259-009-1264-0. PMID: 19838705.","DOI":"10.1007\/s00259-009-1264-0"},{"key":"7275_CR27","doi-asserted-by":"crossref","unstructured":"Jagust W, Mungas D, Decarli C. What does Fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Int J Clin Pract. 2007;871\u20138.","DOI":"10.1212\/01.wnl.0000269790.05105.16"},{"issue":"2","key":"7275_CR28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00259-013-2562-0","volume":"41","author":"NM Kemppainen","year":"2014","unstructured":"Kemppainen NM, Aalto S, Karrasch M, N\u00e5gren K, Savisto N, Oikonen V, et al. Five-year follow-up of 11\u00a0C-PIB uptake in Alzheimer\u2019s disease and MCI. Eur J Nucl Med Mol Imaging. 2014;41(2):283\u20139. https:\/\/doi.org\/10.1007\/s00259-013-2562-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"7275_CR29","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1474-4422(11)70077-1","volume":"10","author":"H Barthel","year":"2011","unstructured":"Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-\u03b2 PET with Florbetaben (18F) in patients with Alzheimer\u2019s disease and healthy controls: A multicenter phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424\u201335. https:\/\/doi.org\/10.1016\/S1474-4422(11)70077-1.","journal-title":"Lancet Neurol"},{"issue":"9","key":"7275_CR30","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s10072-018-3477-0","volume":"39","author":"T Kikukawa","year":"2018","unstructured":"Kikukawa T, Mori E, Kitaguchi H, Tashiro M, Ishii K, Sasaki M, et al. Amyloid deposition and CBF patterns predict the conversion of mild cognitive impairment to dementia. Neurol Sci. 2018;39(9):1597\u2013602. https:\/\/doi.org\/10.1007\/s10072-018-3477-0.","journal-title":"Neurol Sci"},{"key":"7275_CR31","unstructured":"Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R. Diagnostic accuracy of 18F-FDG and 11\u00a0C-PIB-PET for the prediction of short-term conversion to Alzheimer\u2019s disease in subjects with mild cognitive impairment. Int J Clin Pract. 2012;185\u201398."},{"issue":"27","key":"7275_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000000150","volume":"93","author":"Y Ma","year":"2014","unstructured":"Ma Y, Zhang S, Li J, Zheng X, Li Y. Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer\u2019s disease with different lengths of follow-up. Med (United States). 2014;93(27):1\u201312. https:\/\/doi.org\/10.1097\/MD.0000000000000150.","journal-title":"Med (United States)"},{"issue":"7","key":"7275_CR33","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/s00259-024-06631-y","volume":"51","author":"M Cotta Ramusino","year":"2024","unstructured":"Cotta Ramusino M, Massa F, Festari C, Gandolfo F, Nicolosi V, Orini S, Nobili F, Frisoni GB, Morbelli S, Garibotto V. European Inter-Societal consensus on the Biomarker-Based diagnosis of dementia. Diagnostic performance of molecular imaging methods in predicting the progression from mild cognitive impairment to dementia: an updated systematic review. Eur J Nucl Med Mol Imaging. 2024;51(7):1876\u201390. https:\/\/doi.org\/10.1007\/s00259-024-06631-y. Epub 2024 Feb 15. PMID: 38355740.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7275_CR34","doi-asserted-by":"crossref","unstructured":"Sanchez-Catasus A, Stormezand GN, van Laar JP, De Deyn PP, Sanchez Alvarez M, Dierckx RA. FDG-PET for prediction of AD dementia in mild cognitive impairment. A review of the state of the Art with particular emphasis on the comparison with other neuroimaging modalities (MRI and perfusion SPECT). Curr Alzheimer Res. 2017.","DOI":"10.2174\/1567205013666160629081956"},{"issue":"4","key":"7275_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: towards a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"9","key":"7275_CR36","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1093\/brain\/awz194","volume":"142","author":"MJ Pontecorvo","year":"2019","unstructured":"Pontecorvo MJ, Devous MD, Sr, Navitsky M, et al. Relationships between flortaucipir PET Tau binding and amyloid burden, clinical diagnosis, age, and cognition. Brain. 2019;142(9):2638\u201359. https:\/\/doi.org\/10.1093\/brain\/awz194.","journal-title":"Brain"},{"issue":"12","key":"7275_CR37","doi-asserted-by":"publisher","first-page":"e1731","DOI":"10.1212\/WNL.0000000000011535","volume":"96","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Roberts RO, Geda YE, et al. Nonamnestic mild cognitive impairment and the prevalence of neurodegenerative disease. Neurology. 2021;96(12):e1731\u201341. https:\/\/doi.org\/10.1212\/WNL.0000000000011535.","journal-title":"Neurology"},{"issue":"4","key":"7275_CR38","doi-asserted-by":"publisher","first-page":"fcae183","DOI":"10.1093\/braincomms\/fcae183","volume":"6","author":"N Corriveau-Lecavalier","year":"2024","unstructured":"Corriveau-Lecavalier N, Botha H, Gosselin N, et al. Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome. Brain Commun. 2024;6(4):fcae183. https:\/\/doi.org\/10.1093\/braincomms\/fcae183.","journal-title":"Brain Commun"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07275-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07275-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07275-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:08:54Z","timestamp":1757160534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07275-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7275"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07275-2","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was evaluated by the Ethics Research Committee of the University of Navarra and there were no ethical inconvenien.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study at the time of the PET scan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors affirm that human research participants provided informed consent for the publication of the images.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Only Javier Arbizu received research grants from Life Molecular Imaging and Siemens through Clinica Universidad de Navarra, and lecture fees from Novartis\/Advanced Accelerator Applications, Eli Lilly, GE Healthcare, Life Molecular Imaging, Siemens and Zambon. \u2018Theothers authors have no relevant financial or nonfinancial interests to disclose\u2019.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}